Screener
Iovance Biotherapeutics, Inc. IOVA Ratios & Valuation
| Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | ||
|---|---|---|---|---|---|---|
| Profitability | ||||||
| Gross margin | 48.4%+15.0pp | 39.4%+6.9pp | 34.3%+0.1pp | 33%+4.3pp | 33.4%+48.1pp | |
| Operating margin | -92.7%+77.3pp | -127.2%+60.3pp | -153.1%+87.8pp | -166.3%+307pp | -170%+1,231pp | |
| Net margin | -89.1%+72.4pp | -123.9%+52.6pp | -148.4%+78.5pp | -158.8%+292pp | -161.4%+1,182pp | |
| Returns | ||||||
| Return on equity | -40.4%+12.8pp | -47.5%+4.3pp | -55.5%+2.0pp | -53.9%+2.8pp | -53.2%+12.2pp | |
| Return on invested capital | -46.7%+19.9pp | -59.5%+2.9pp | -65.2%+4.6pp | -65.2%+12.9pp | -66.6%+27.3pp | |
| Efficiency | ||||||
| Asset turnover | 0.4×+0.1× | 0.3×+0.1× | 0.3×+0.1× | 0.3×+0.2× | 0.3×+0.2× | |
| Liquidity | ||||||
| Current ratio | 4.3×+1.1× | 3.6×-0.6× | 3.2×-0.5× | 3.4×-0.8× | 3.3×-1.9× | |
| Leverage | ||||||
| Debt-to-equity | 0.1×0.0× | 0.1×0.0× | 0.1×0.0× | 0.1×0.0× | 0.1×0.0× | |
| Per Share | ||||||
| Book value per share | $1.64-21.7% | $1.72-27.5% | $1.95-20.2% | —— | $2.09-22.6% | |
| Valuation | ||||||
| Market capitalization | $2.77B+222% | $1.45B+32.4% | $1.08B-51.9% | $785.22M-70.6% | $627.8M-70.6% | |
| Price / sales | 8.5×+5.0× | 5.1×-0.1× | 4.1×-9.6× | 3.1×-26.3× | 2.6×-62.6× | |
| Price / book | 3.8×+2.5× | 2×+0.6× | 1.6×-1.6× | 1.1×-2.3× | 0.9×-1.9× |
FAQ
- What are Iovance Biotherapeutics, Inc.'s profit margins?
- Iovance Biotherapeutics, Inc. (IOVA) runs a 48.4% gross margin and a -92.7% operating margin, with a -89.1% net margin.
- Where do Iovance Biotherapeutics, Inc.'s ratios come from?
- Every ratio is computed from Iovance Biotherapeutics, Inc.'s SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.
